Syndax Pharmaceuticals (SNDX) Interest Expenses (2015 - 2026)

Syndax Pharmaceuticals' Interest Expenses history runs 12 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 47.5% year-over-year to $11.8 million in Q1 2026; TTM through Mar 2026 was $28.1 million, a 116.77% increase from a year earlier, with the FY2025 full-year figure at $56.9 million, down 78.01% from the prior year.
• Interest Expenses advanced to $11.8 million in Q1 2026 per SNDX's latest filing, from $8.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $11.8 million in Q1 2026 and bottomed at $23000.0 in Q3 2024.
• The 5-year median for Interest Expenses is $786500.0 (2024), against an average of $2.9 million.
• Across the five-year window, Interest Expenses slumped 94.95% in 2024 and soared 35986.96% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $41000.0 in 2022, then surged by 53.66% to $63000.0 in 2023, then surged by 7641.27% to $4.9 million in 2024, then jumped by 70.19% to $8.3 million in 2025, then soared by 42.17% to $11.8 million in 2026.
• Per Business Quant, the three latest SNDX Interest Expenses figures stand at $11.8 million (Q1 2026), $8.3 million (Q3 2025), and $6.2 million (Q2 2025).